Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location.
Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 73.9K |
| Three Month Average Volume | -100,000 |
| High Low | |
| Fifty-Two Week High | 16 USD |
| Fifty-Two Week Low | 9.71 USD |
| Fifty-Two Week High Date | 19 Jul 2024 |
| Fifty-Two Week Low Date | 23 Aug 2024 |
| Price and Volume | |
| Current Price | 11.54 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -6.56% |
| Thirteen Week Relative Price Change | -99,999.99% |
| Twenty-Six Week Relative Price Change | -99,999.99% |
| Fifty-Two Week Relative Price Change | -99,999.99% |
| Year-to-Date Relative Price Change | -99,999.99% |
| Price Change | |
| One Day Price Change | 2.12% |
| Thirteen Week Price Change | -99,999.99% |
| Twenty-Six Week Price Change | -99,999.99% |
| Five Day Price Change | 15.40% |
| Fifty-Two Week Price Change | -99,999.99% |
| Year-to-Date Price Change | -99,999.99% |
| Month-to-Date Price Change | -2.20% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.33653 USD |
| Book Value Per Share (Most Recent Quarter) | 1.79284 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.33653 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.79284 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.08279 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.43856 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.40686 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.23359 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.1153 USD |
| Normalized (Last Fiscal Year) | -1.23359 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.23359 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.1153 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.23359 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.1153 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.30609 USD |
| Cash Per Share (Most Recent Quarter) | 2.66881 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.13626 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.01797 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.13418 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -152 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -79.06% |
| Pretax Margin (Last Fiscal Year) | -85.54% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -91.58% |
| Operating Margin (Trailing Twelve Months) | -83.88% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -85.75% |
| Net Profit Margin (Trailing Twelve Months) | -79.28% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -74.62% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 616.40% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 16.47% |
| EPS Change (Trailing Twelve Months) | 59.03% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 7 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -62,134,000 |
| Net Debt (Last Fiscal Year) | -76,971,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 8 |
| Price to Sales (Trailing Twelve Months) | 9 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -50,688,000 |
| Free Cash Flow (Trailing Twelve Months) | -49,687,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -24.12% |
| Return on Assets (Trailing Twelve Months) | -99,999.99% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -28.67% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -99,999.99% |